National Heart Centre Singapore
nhcs.com.sgTotal trials
62
Active
20
Phase 3
0
Total enrollment
7,342,897
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Renin-angiotensin-aldosterone system inhibitors | — | — | — | — | — | 1 | |
| Beta blocker | — | — | — | — | — | 1 | |
| SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product | — | — | — | — | — | 1 | |
| Hyperpolarized 13C-pyruvate | — | — | — | — | — | 1 | |
| MEI6570 | — | — | — | — | — | 1 |
Next readouts
- 2022-06-30
- 2025-09-01
- 2028-05-31
Top conditions
- Coronary Artery Disease11
- Heart Failure6
- Cardiovascular Diseases6
- Ischemic Heart Disease5
- Hypertension4
- Coronary Stenosis3
- STEMI3
- Cardiac Ageing3
Frequently asked questions about National Heart Centre Singapore
- How many clinical trials does National Heart Centre Singapore have on ClinicalTrials.gov?
- National Heart Centre Singapore is listed as the lead sponsor on 62 clinical trials in ClinicalTrials.gov, 20 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National Heart Centre Singapore's trials are in Phase 3?
- 0 of National Heart Centre Singapore's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does National Heart Centre Singapore focus on?
- National Heart Centre Singapore's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Heart Failure, Cardiovascular Diseases, Ischemic Heart Disease, Hypertension.
- When are National Heart Centre Singapore's next clinical trial readouts?
- National Heart Centre Singapore has 3 upcoming primary-completion readouts tracked here; the soonest is “Asian Diabetes Outcomes Prevention Trial”, expected around 2022-06-30.